Product and Company News from the 7/22 News Brief
Biopharmaceutical company QLT announced that it has received final approval from the FDA to market Aczone (dapsone) Gel, for the topical treatment of acne vulgaris.
Allergan and Pharmacopeia have reached an agreement to research compounds for age-related macular degeneration (AMD). Allergan seeks to strengthen its ocular diseases franchise via possible future acquisitions of Pharmacopeia's novel compounds targeting angiogenesis.
AstraZeneca has agreed to pay up to $340m in cash and conditional milestone payments to Avanir, to license compounds for cardiovascular disease.